Harrow (NASDAQ:HROW) Shares Climb 5% - Still a Buy?

Key Points

• Harrow shares rose 5% to about $29.70 on Friday, although trading volume was 96% below its average.
• For its latest quarter, Harrow reported EPS of $0.25 versus estimates of $0.19 and revenue of $99.3 million, slightly above expectations.
• Analyst views are mixed: six rate the stock Buy, one Hold and two Sell, resulting in an average Hold rating and a $66.20 average price target. HC Wainwright also improved its earnings forecasts, projecting a smaller loss.

Harrow, Inc. (NASDAQ:HROW - Get Free Report) traded up 5% during trading on Friday. The company traded as high as $29.14 and last traded at $29.7020. 27,980 shares traded hands during trading, a decline of 96% from the average daily volume of 695,777 shares. The stock had previously closed at $28.30.

Recent Harrow Headlines

Here are a few of the latest headlines about HROW:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.40 from a loss of $0.57, and narrowed its projected Q2 2027 loss to $0.10 per share from $0.12. Harrow analyst estimate report
• Positive Sentiment: An article contends HROW still looks undervalued despite a reported 229% gain over three years, potentially reinforcing a bullish view of its longer-term prospects. Harrow stock still looks undervalued
• Neutral Sentiment: Harrow management plans to meet investors at the Craig-Hallum Alpha Select Conference on Nov. 17 and present at the Jefferies Global Healthcare Conference on Nov. 18. The events offer investor access, but no new business or financial results were announced. Harrow investor conference announcement

Wall Street Analysts Forecast Growth

HROW has been the subject of several research analyst reports. Leerink Partners assumed coverage on shares of Harrow in a research report on Wednesday, September 9th. They issued an "outperform" rating and a $45.00 target price for the company. BTIG Research reaffirmed a "buy" rating and set a $63.00 price target on shares of Harrow in a research report on Wednesday. Weiss Ratings reiterated a "sell (e+)" rating on shares of Harrow in a research note on Friday, October 16th. Zacks Research cut Harrow from a "hold" rating to a "strong sell" rating in a research note on Tuesday, November 3rd. Finally, Wall Street Zen upgraded Harrow from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $66.20.

Harrow Stock Up 7.8%

The company has a debt-to-equity ratio of 10.15, a current ratio of 2.29 and a quick ratio of 2.08. The stock's fifty day simple moving average is $30.94 and its 200-day simple moving average is $37.59. The stock has a market cap of $1.15 billion, a P/E ratio of -39.07 and a beta of 0.18.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.06. The business had revenue of $99.30 million for the quarter, compared to analysts' expectations of $98.59 million. Harrow had a negative return on equity of 69.81% and a negative net margin of 9.39%. On average, research analysts anticipate that Harrow, Inc. will post -0.02 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HROW. First Trust Advisors LP grew its holdings in Harrow by 40.4% in the 3rd quarter. First Trust Advisors LP now owns 140,833 shares of the company's stock worth $4,338,000 after buying an additional 40,518 shares in the last quarter. Cibc World Market Inc. grew its holdings in Harrow by 57.1% during the third quarter. Cibc World Market Inc. now owns 13,350 shares of the company's stock worth $411,000 after acquiring an additional 4,850 shares during the period. Drive Wealth Management LLC acquired a new position in Harrow during the third quarter worth about $2,057,000. Westside Investment Management Inc. raised its position in Harrow by 4.7% in the third quarter. Westside Investment Management Inc. now owns 234,526 shares of the company's stock worth $7,223,000 after acquiring an additional 10,475 shares in the last quarter. Finally, Woodmont Investment Counsel LLC raised its position in Harrow by 4.6% in the third quarter. Woodmont Investment Counsel LLC now owns 116,899 shares of the company's stock worth $3,600,000 after acquiring an additional 5,089 shares in the last quarter. Institutional investors own 72.76% of the company's stock.

About Harrow

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.